Skip to main content
EJNMMI Research
Fig. 13 | EJNMMI Research

Fig. 13

From: Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model

Fig. 13

Percent change relative to the 15-kBq-treated mice in the average whole-body and organ weights of tumor-free mice treated with 225Ac-anti-PD-L1 (3 mg/kg, 60 μg) at increasing administered activities of 15, 22, 30, 37, and 44 kBq (n = 4 to 5 mice/point). *p ≤ 0.01 relative to 15 kBq; **p ≤ 0.01 relative to 22 kBq

Back to article page